We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Advertising (272)
- COVID-19 (163)
- Safety monitoring and information (96)
- Legislation (93)
- Compliance and enforcement (65)
- Manufacturing (52)
- Vaping hub (51)
- Labelling and packaging (35)
- Scheduling (national classification system) (27)
- Import and export (26)
- Medicinal cannabis hub (25)
- Sunscreens (16)
- Shortages and supply disruptions (14)
- Weight loss products (14)
- Committees and advisory bodies (9)
- Cosmetics (5)
- Unique Device Identification (UDI) hub (4)
- Clinical trials (3)
- Fees and payments (2)
- Prescription opioids hub (2)
- Urogynaecological (transvaginal) surgical mesh hub (2)
- Breast implant hub (1)
Search
150 result(s) found, displaying 126 to 150
-
News articlesInformation on generic prescription medicines
-
Media releasesNo lasting increase in consumption following up-scheduling of low-dose products
-
Media releasesThe reforms will enable the safe and effective prescribing and use of opioids while maintaining access for patients who need them.
-
BlogHow to find information about the inactive ingredients in your medicines.
-
News articlesIn response to the COVID-19 pandemic, the TGA is implementing Serious Shortage Medicine Substitution Notices
-
Media releasesCommunity pharmacists to enforce new limits on dispensing and sales of prescription and over-the-counter medicines
-
-
Media releasesXofluza approved as part of an international work-sharing initiative between the TGA, Health Canada and Swissmedic
-
Media releasesMeasles vaccine testing shows the vaccine meets required standards
-
Media releasesAcalabrutinib receives approval through the second international collaborative review initiative between the TGA, FDA and Health Canada
-
News articlesGeneral information for consumers on prescription opioids
-
Regulatory decision noticesJapan has recently been added to the list of Foreign Countries and Jurisdictions determined to be comparable overseas regulators
-
Media releasesInternational Collaborative Review Initiative gives provisional approval of lenvatinib in combination with pembrolizumab
-
News articlesAre you aware of the risks associated with cosmetic injections?
-
Media releasesThe Federal Court has imposed substantial penalties on Peptide Clinics Australia
-
News articlesThe prescription medicines regulatory reforms include changes that will bring medicines to market sooner in Australia, while maintaining a robust framework for safety, quality and efficacy.
-
News articlesCabozantinib (CABOMETYX) is the first medicine to be registered via the new COR-A pathway
-
Media releasesApalutamide (Erlyand) is the first medicine approved via ACSS Consortium’s NCE working group
-
Regulatory decision noticess23 instruments supporting the new COR process have been updated.
-
Media releasesThe medicines’ regulator is not proposing and will not be stopping GPs from prescribing high dose opioids
-
-
-
Media releasesThe TGA begins piloting electronic submissions for registered medicines using the eCTD format, supported by updated software and a revised Module 1 aligned with European standards.
-
-